Novo Nordisk proposed $9.1 billion acquisition of Metsera
We are advising Novo Nordisk on the transaction
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
GSK exclusive license agreement with Empirico
We advised GSK on the transaction
Turn Therapeutics direct listing
We advised Turn Therapeutics on its Nasdaq listing
Amulet Capital Partners sale of SSI Strategy to Clinigen
We are advising Amulet Capital Partners and SSI Strategy on the sale
UST sale of HealthProof to Bain
We advised UST on the transaction
GSK agreements with Hengrui Pharma to develop up to 12 innovative medicines
We are advising GSK on the transaction
Omada Health $172.6 million IPO
The shares are listed on the Nasdaq Global Select Market
Hinge Health $503 million IPO
The shares are listed on the New York Stock Exchange
Nova Biomedical $2.2 billion acquisition by Advanced Instruments
We are advising Nova Biomedical on the transaction
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction